Why the Two Routes Feel Like Separate Healthcare Systems
When GLP-1 medicines began reaching mainstream UK awareness, most coverage framed access as a simple question: ask your GP or pay privately. The reality is considerably more layered. The NHS pathway and the private pathway are governed by different eligibility rules, different monitoring obligations, and fundamentally different financial models — and the gap between what each delivers in practice has grown wider as demand has surged.
Understanding both routes is not just a matter of comparing price tags. The oversight structures around each pathway carry real clinical consequences, particularly for patients managing conditions that interact with the metabolic changes these medicines produce.
NHS Eligibility: BMI, Comorbidities, and the Specialist Pathway
NHS access to licensed GLP-1 weight-management medicines — primarily Wegovy (semaglutide) and Mounjaro (tirzepatide) — runs through a structured eligibility framework overseen by NICE guidance. The threshold currently centres on a BMI of 35 or above alongside at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or obstructive sleep apnoea. In some regions, access operates through specialist weight-management services — commonly called Tier 3 or Tier 4 services — rather than directly via a GP.
This specialist-pathway structure creates the first hidden cost: time. Referrals from primary care to a specialist weight-management service can take six months to over a year in many NHS trusts, and that is before the appointment itself. Patients who qualify on paper may still face extended waits before treatment begins. NHS eligibility rules also vary across devolved nations, meaning access in Scotland, Wales, and Northern Ireland does not follow exactly the same criteria as in England.
What NHS Access Actually Costs Patients
For patients who reach the point of an NHS prescription, the upfront medicine cost is covered, and standard prescription charges apply — currently a fixed charge per item or covered by a prepayment certificate. But the total cost of the NHS pathway is not zero, and it is not frictionless.
The less-visible costs include GP appointment time, monitoring tests, travel to specialist appointments, and the extended period of potential health consequences while waiting for treatment to begin. There is also no guarantee that access continues once initiated — NHS prescribing can be paused or discontinued depending on service capacity, supply-chain issues, or changes in the patient's clinical picture.
Private Clinic Pricing: Consultation Fees, Pen Costs, and Dose Titration
Private clinics offering GLP-1 prescriptions vary considerably in their fee structures, but most operate on a combination of an initial consultation fee, a monthly prescription cost, and sometimes additional charges for monitoring or nurse support. Initial consultations typically run from roughly £50 to £200 depending on the clinic format — some are conducted entirely online — and the medicine cost is paid separately.
The monthly cost of the medicine itself is the largest ongoing expense. Mounjaro pens at lower dose levels have been available privately from around £130 to £180 per month, while Wegovy at maintenance doses can cost significantly more. As doses titrate upward over the standard four-to-five month escalation period, the monthly spend rises accordingly. Annual costs for a patient at full maintenance dose easily reach four figures. For the NHS versus private GLP-1 pathway comparison, the total cost differential over a two-year treatment course can run into thousands of pounds.
The Oversight Gap: What You Gain and Lose Outside the NHS
The NHS pathway, for all its access friction, delivers something the private market does not uniformly provide: a structured clinical framework. NHS-prescribed GLP-1 medicines come with monitoring expectations, prescriber accountability, and an integrated record that connects to the rest of your healthcare. A prescriber within the NHS is embedded in a system designed to catch adverse effects, manage drug interactions, and respond to complications.
Private clinics operate outside that integrated framework. Some are excellent — staffed by qualified prescribers who order appropriate baseline bloods, follow established titration protocols, and maintain thorough records. Others are not. The quality of oversight in the private sector ranges from genuinely clinical to commercially perfunctory, and patients without clinical training cannot always distinguish between the two from a website.
Red Flags in Private GLP-1 Clinics and How to Vet One Properly
The rapid growth of private weight-loss medicine services has created a market where scrutiny is uneven. Knowing what to check before joining a weight-loss clinic is not a minor due-diligence step — it is a patient safety matter.
Legitimate private clinics will require a medical consultation with a named, qualified prescriber before issuing a prescription. They will ask about relevant medical history, current medications, and contraindications. They will order or request baseline blood tests, including HbA1c, liver function, and thyroid markers. They will have a clear monitoring protocol and will not prescribe to patients with conditions that contraindicate GLP-1 therapy — including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Clinics that offer instant prescriptions following a brief questionnaire, that cannot identify the prescriber by name and qualifications, or that pressure patients toward higher doses or longer supply commitments without clinical justification are operating below the standard a patient should accept.
How to Start the NHS Conversation and What to Do While You Wait
The most practical first step for patients who believe they may qualify for NHS treatment is a direct conversation with their GP. Coming prepared — knowing the current NICE eligibility criteria, understanding which specialist services operate locally, and being clear about the weight-related conditions that are affecting quality of life — makes that conversation more productive. GPs vary in their familiarity with the current GLP-1 prescribing landscape, and some will need supporting information to initiate a referral.
For patients facing a long NHS wait, the interim period is not simply dead time. Dietary changes, structured physical activity, and addressing sleep and stress all interact with the metabolic pathways these medicines work on. Patients who arrive at treatment with some of those foundations in place tend to have a better overall trajectory than those who treat the medicine as the only intervention.
The choice between NHS and private is, for many patients, partly resolved by circumstances: those who cannot wait and can afford private costs will go private; those who cannot afford private costs will pursue the NHS route and manage the wait. The more important question is whether, whichever route is chosen, the clinical oversight is adequate — because the medicine works best when it is monitored well.